Pipeline

Precision Medicines to Transform Patient Lives

Our pipeline of therapeutics is being developed to specifically target the causative pathological mechanisms of a number of NETs-based diseases and beyond.

WARNING: Do NOT edit any of this Pipeline in this Designer Interface — It is very fragile and you WILL 100% BREAK IT! only make changes to pipeline in the CMS. If you need a change that cannot be fixed in CMS, contact developer at edward.goin@gmail.com

exDNASE™
PLATFORM
Mechanism of Action
Discovery
Phase
IND-Enabling
Phase 1
Phase 2
NTR-L301
COVID-19
Resolution of hyperinflammation
Late Phase 1
NTR-L301
Lupus
Disruption of NET-Immune Complexes
Mid IND Enabling
NTR-L302
Undisclosed
Undisclosed
Mid IND Enabling
NTR-L303
Genetic Deficiency
Enzyme Replacement Therapy
Early IND Enabling
NTR-L201
Undisclosed
Undisclosed
Late Discovery
NTR-101
Undisclosed
Various Indications
Late Discovery
NEU-101
Surface Inflammation
Undisclosed
Early Discovery
No items found.
No items found.
No items found.
No items found.
No items found.

Our Approach

Neutrolis’ unique approach allows for detailed interrogation of NET-based diseases and development of first-in-class therapeutics.

Step One

Detailed mechanistic understanding of neutrophil diseases using proprietary humanized mouse models

Step Two

In silico and rational design of therapeutic candidates targeted to disease mechanisms

Step Three

Identification of genetically relevant patient populations using real-world evidence to enable the most efficient validation and characterization of clinical impact

Step Four

Rapid iterative prototyping and scalable manufacturing of lead molecules for clinical development

Step Five

Measurement of biomarkers for patient stratification and assessment of pharmacodynamic effects of therapeutic candidates 

prev
next
prev
next

NET biomarkers drive precision therapies

Neutrolis systematically identifies biomarkers that provide high confidence in the selection, treatment and monitoring of patients that are candidates for Neutrolis’ therapies. We leverage real-world evidence, genetics, and biomarkers to clearly define populations at a genetic and physiological level. Neutrolis uses robust detection methods to select patients likely to respond to anti-NETs therapies. In addition to patient stratification, our pharmacodynamic biomarkers also allow us to monitor treatment response to our therapies.

1
NET fragments are released and circulate in the blood

In patients with inflammatory or autoimmune diseases, such as lupus, NETs are formed in tissues and organs. Due to low levels of intrinsic NET disassembly, small fragments of NETs circulate in the blood.

2
Identification of drug target exposure from patient's blood

Blood drawn and processed from patients will contain NET fragments, which are indicative of Neutrolis' drug target exposure.

3
Molecular analysis of NET fragments aid precision therapy

Molecular biomarker analysis on NET fragments provide additional insights into treatment strategies for patients.